Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
Patients with relapsed or refractory multiple myeloma who are treated with new therapy combinations remain on their treatments far shorter than those participating in clinical trials, a study found. ... Read more
Newly diagnosed multiple myeloma patients respond better to treatment when Empliciti (elotuzumab) is added to a combination of Revlimid (lenalidomide) and dexamethasone, a study from Japan demonstrates. The treatment ... Read more
Weighing individual cancer cells could help doctors predict how multiple myeloma patients will respond to treatments, a Massachusetts Institute of Technology study reports. The findings could help doctors choose the right ... Read more
The U.S. Food and Drug Administration (FDA) has granted Celgene and Bluebird Bio’s bb2121 — the first CAR T-cell therapy for multiple myeloma — Breakthrough Therapy Designation. Regulators at the ... Read more
The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume, after being put on partial hold in September 2017, ... Read more
Poseida Therapeutics is developing CAR T-cell therapies that can get rid of cancer-generating bone marrow cells before a blood cancer patient receives a stem cell transplant. This approach is ... Read more
Janssen plans to share new data from Phase 3 trials of Darzalex (daratumumab) for multiple myeloma at the 59th American Society of Hematology (ASH) Annual Meeting, scheduled for Dec. 9-12 in ... Read more